DUBLIN--(BUSINESS WIRE)--The "Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Spinocerebellar Ataxia - Pipeline Review, H2 ...

GAITHERSBURG, Md., Jan. 26, 2021 /PRNewswire/ -- GeneDx, Inc., a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK ...

To report optical coherence tomography (OCT) findings in order to detect subclinical alterations of the afferent visual pathways in spinocerebellar ataxia 3 (SCA-3). Nine genetically confirmed ...

NEW HAVEN, Conn., May 23, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and ...

SLS-005 contains the active ingredient trehalose, a low molecular weight disaccharide (0.342 kDa) that has been shown to penetrate muscle and cross the blood brain barrier. The Food and Drug ...

The FDA has accepted Seelos Therapeutics Inc's (NASDAQ: SEEL) Investigation New Drug application to study SLS-005 (trehalose injection, 90.5 mg/mL) for spinocerebellar Ataxia (SCA). The FDA has also ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and ...

Ataxia is a degenerative disease affecting the nervous system, presenting poor coordination and movement, difficulties with speech, walking, fine motor skills, swallowing, and vision. It mainly ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Biohaven is on the cusp of a new drug application filing in a rare neurodegenerative disorder that currently has no approved therapies, a surprising development for a molecule with a long list of ...